E

Buildings walls versus building cathedrals

The devil is in the finer details...

October 27, 2020
E

New developments in the KRAS landscape

An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.

October 15, 2020
E

Controversial developments in pancreatic cancer

What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?

July 30, 2020
E

What’s the skinny on a new IO target in oncology R&D?

A new emerging IO target of interest caught out attention, now what?

July 28, 2020
E

A new dawn for epigenetic therapy in oncology

A novel epigenetic target may have far-reaching outcomes for cancer patients

July 23, 2020
E

New developments in CAR-T cell therapies including controversial ones

The ups and downs of CAR-T cell therapy development continues apace

July 8, 2020
E

Reflections on the latest lurbinectedin and abemaciclib developments

What can we learn from the recent announcements for lurbinectedin in 2L SCLC and the CDK4/6 inhibitors in adjuvant HR+HER2- early breast cancer.

June 17, 2020
E

Solid tumour winners and losers at ASCO20

Highlights from several solid tumour trials in both early and late stage disease.

June 9, 2020
E

Can we add fire to the immune system with TIGIT?

A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer

June 1, 2020
E

One swallow does not a summer make

Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20

April 27, 2020
E

Reflections on new developments in the KRAS niche

Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2

April 20, 2020
E

Impact of Covid–19 on Cancer Conferences

A look at the revised schedule and timelines for upcoming Spring cancer conference season

April 13, 2020
E

Will bromodomain inhibitors and PROTACs make an impact?

A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC

September 4, 2019
E

Novel DDR combinations and regimens that could make a difference

Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space

August 16, 2019
E
Lightning bolt

Is the BMS CheckMate-227 trial a hit or miss in lung cancer?

Our latest analysis of the ever evolving NSCLC landscape following BMS’s announcement on CheckMate-227

July 25, 2019
E
Cambridge from Bay Bay Boston

An in-depth look at Neon’s updated neoantigen vaccine data

Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?

July 17, 2019
E

Ever decreasing circles in oncology R&D

Analysis and predictions of two oncology phase 3 readouts coming soon...

February 4, 2019
E

An update on key SCLC trials

A look at the CheckMate-331 and CheckMate-451 study and other SCLC trials

October 12, 2018
E

An early cell therapy product to watch out for

Cell therapy is a very broad church - here's an interesting approach to keep an eye on

September 19, 2018
E

New Insights on BCMA BiTEs and CAR T cell therapies in Myeloma

Update on BCMA, SLAMF7 and other targets in multiple myeloma

September 11, 2018
E

ASCO18 Reader Q&A

It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some…

May 25, 2018
E

Why we should be cautious about IO-IO combination trials

A look at some of the issues underlying IO-IO combos and whether they can help us assess if these trials will succeed - or not.

February 28, 2018
E

SCLC – An in-depth look at ROVA-T and TRINITY

A look at ROVA-T's chances in the upcoming phase 2 TRINITY trial readout

October 25, 2017
E

BSB Q&A on IMDZ and 1L NSCLC

A look at the trials and tribulations for Immune Design's CMB305 and what's the latest in 1L NSCLC

October 20, 2017
E

$PBYI – plain sailing or death by a thousand cuts?

A look at the FDA briefing docs on Puma's neratinib

May 23, 2017
E

On Kite’s cerebral edema and Genentech’s IMvigor211 miss

We've been overdue a correction in the irrational exuberance around IO... is this the tip of the iceberg?

May 10, 2017
E

BSB Mailbag on ROS1, ALK and TRK inhibitors

BSB Reader Mailbag on TRK/ROS1/ALK inhibitors

April 28, 2017
E

Asking Good Questions is both an Art and a Science

Latest BSB reader Q&A looks at 5 questions from subscribers

March 16, 2017
E

On APHINITY, SOLO2 and Immunomedics

Reader Q&A on women's cancers relating to HER2, PARP and TNBC...

February 13, 2017
E

Can we expect more surprises in 1L NSCLC?

A look at the how several major phase 3 trial readouts will affect the 1L NSCLC landscape

January 18, 2017
E

September BSB Reader Mailbag

Latest BSB mailbag covers targeted therapies, immunotherapy and #ESMO16

September 29, 2016
E

Biotech Mailbag – Jounce & the CAR T Race to Market

July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...

July 27, 2016
E

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016
E

Biotech Strategy Blog Mailbag Monday

Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news

March 21, 2016
E

Q&A on hot topics in CAR T cell therapies

Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies

November 18, 2015
E

Biotech Strategy questions answered on BRAF, MEK, immunotherapy, mirvetuximab soravtansine and venetoclax

This month's Biotech Strategy Blog mail bag.

July 17, 2015
E

Biotech Strategy questions answered on neratinib, bavituximab, enzalutamide and more!

Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...

June 17, 2015